Previous studies have revealed that overexpression of TXNRD1 modulates drug-specific cytotoxic responses [18] and inhibition of the TXNRD1 enhances the efficacy of some chemotherapeutics, such as improving ibrutinib’s anti-EGFR activity in lung cancer [19]. The gene discussed is TXNRD1; the disease is lung carcinoma.